Sachdev Amit 4

What Happened

• Amit Sachdev, EVP, Chief Patient & External Affairs Officer at Vertex Pharmaceuticals (VRTX), was granted 5,789 restricted stock units (RSUs) on Feb 17, 2026 (grant reported at $0.00). To satisfy a tax liability, 2,140 shares were withheld/disposed at $483.75 per share, totaling $1,035,225. Net from this award: 3,649 RSUs (5,789 granted less 2,140 withheld), subject to the vesting schedule.

Key Details

• Transaction date: 2026-02-17; filing date: 2026-02-19 (timely).
• Grant: 5,789 RSUs (code A), acquisition price reported $0.00.
• Withholding/tax payment: 2,140 shares (code F) disposed at $483.75 each for $1,035,225.
• Shares owned after transaction: not specified in the Form 4 filing.
• Footnote: F1 — the RSU award vests in installments beginning Feb 20, 2027.
• This withholding was to cover tax liability, not an open-market sale.

Context

• RSU grants are compensation and vest over time; the award itself is not an immediate purchase signal. The withheld 2,140 shares were used to pay taxes (routine) rather than indicating a voluntary sell. For investors, purchases or open-market buys are generally a stronger bullish indicator than compensation grants or mandatory tax withholding.